Background: There is considerable variation in progressive brain volume changes in schizophrenia. Whether this is related to the clinical heterogeneity that characterizes the illness remains to be determined. This study examines the relationship between change in brain volume over time and individual variation in psychopathology, as measured by five continuous symptom dimensions (i.e. negative, positive, disorganization, mania and depression). Methods: Global brain volume measurements from 105 schizophrenia patients and 100 healthy comparison subjects, obtained at inclusion and 5-year follow-up, were used in this study. Symptom dimension scores were calculated by factor analysis of clinical symptoms. Using linear regression analyses and independentsamples t-tests, the relationship between symptom dimensions and progressive brain volume changes, corrected for age, gender and intracranial volume, was examined. Antipsychotic medication, outcome and IQ were investigated as potential confounders. Results: In patients, the disorganization dimension was associated with change in total brain (β = − 0.295, p = 0.003) and cerebellar (β = − 0.349, p b 0.001) volume. Furthermore, higher levels of disorganization were associated with lower IQ, irrespective of psychiatric status (i.e. patient or control). In healthy comparison subjects, disorganization score was not associated with progressive brain volume changes. Conclusion: Heterogeneity in progressive brain volume changes in schizophrenia is particularly associated with variation in disorganization. Schizophrenia patients with high levels of disorganization exhibit more progressive decrease of global brain volumes and have lower total IQ. We propose that these patients form a phenotypically and biologically homogenous subgroup that may be useful for etiological (e.g., genetic) studies.
Introduction
The presence of structural brain abnormalities in schizophrenia has been well established (DeLisi et al., 1995 (DeLisi et al., , 1997 Shenton et al., 2001) . The most consistently reported abnormalities include enlargement of the ventricles and reductions of whole brain and gray matter volume. Longitudinal neuroimaging studies have shown that these brain volume abnormalities are progressive, although heterogeneity in brain change over time is considerable across individual patients (Pantelis et al., 2005; Hulshoff Pol and Kahn, 2008) . In part, the heterogeneity may be related to the broad diversity in signs and symptoms that characterizes schizophrenia (DeLisi et al., 1998; Lieberman et al., 2001; Andreasen et al., 2011) . The aim of the present study is to examine whether individual variation in lifetime rated schizophrenia symptom dimensions is associated with heterogeneity in progressive brain volume changes.
Studies examining the relationship between symptomatology and progressive brain volume changes are limited in number and have yielded inconsistent findings. In a review of progressive brain changes in schizophrenia, Hulshoff report that more severe negative symptoms have been linked to more pronounced brain volume loss, but that most studies examining clinical parameters in relation to possible change in brain volume over time find no such associations. The lack of association may be due to clinical heterogeneity; indeed, various approaches to define a more homogenous phenotype have been employed. The use of symptoms to divide schizophrenia patients into more uniform subgroups is the most common method (Buchanan and Carpenter, 1997) . More recently, factor-analytic studies have attempted to characterize psychopathology in terms of quantitative symptom dimensions. Liddle (1987) applied factor-analysis to symptoms rated by the Comprehensive Assessment of Symptoms and History (CASH) (Andreasen et al., 1992) and identified three symptom dimensions: psychomotor poverty, reality distortion and disorganization. Other studies using factor analysis to derive symptom dimensions report on factor solutions including 4 to 11 factors, depending on the content of the items included in the analyses (Peralta and Cuesta, 2001 ). While most of these studies were restricted to patient samples, Derks et al. (in press ) performed factor-analysis on CASH-items in 4286 patients, their relatives and community controls. Lifetime-rated symptoms and observational items of the CASH were used as they are considered to better reflect genetic vulnerability and are less influenced by (antipsychotic) treatment compared to present state symptoms. The analyses revealed the presence of negative, positive, disorganized, depressive and manic symptom dimensions.
The relationship between symptom dimensions and cross-sectional brain volume measures has been studied previously. In a voxel based morphometry (VBM) study in 99 schizophrenia patients and 113 matched healthy comparison subjects, Nenadic et al. (2010) reported on volume reductions in prefrontal cortices and thalamus in patients with predominantly negative symptoms, whereas medial temporal and cerebellar gray matter reductions were mostly present in a disorganized subgroup. Another VBM study, in 175 schizophrenia patients and 177 healthy comparison subjects, also reported on selective structural correlates of symptom dimensions. A negative symptom dimension was found to correlate with gray matter reductions in orbitofrontal, prefrontal and temporal cortices and limbic structures, while disorganization was associated with reductions in temporal, insular and medial prefrontal cortices (Koutsouleris et al., 2008) . Findings on the positive symptom dimension are inconsistent, as correlations with both decreased (Koutsouleris et al., 2008; Nesvåg et al., 2009 ) and increased gray matter volume (Whitford et al., 2005) have been reported. To the best of our knowledge, the relationship between lifetime rated schizophrenia symptom dimensions and change in brain volume over time has not been investigated.
The aim of this study is to explore the association between CASH derived lifetime rated symptom dimensions and progressive brain volume changes over a 5-year interval in schizophrenia patients and healthy comparison subjects.
Methods

Subjects
For the present study a total of 105 patients (81 men, 24 women) with schizophrenia and related spectrum disorders and 100 healthy comparison subjects (69 men, 31 women) from two previously published cohorts (van Haren et al., 2008; Cahn et al., 2009) were included. For all subjects global brain volume measurements at inclusion and 5-year follow-up and at least one CASH-interview with no more than 20 missing items (25%) were available. The CASH interview was included at baseline (N patients = 14; N controls =5), one year after baseline (N patients = 14; N controls = 5), or at 5-year follow-up (N patients = 77; N controls = 90). All patients were recruited from the Utrecht Schizophrenia Project and the First-Episode Schizophrenia Research Program and were followed for a period of five years to examine brain morphology in relation to clinical variables, such as outcome, medication and cannabis use. All subjects provided written consent prior to participation. Subjects with major medical or neurological illness were excluded. Patients were recruited from various outand inpatient clinics. The amount and type of medication prescribed between inclusion and 5-year follow-up was recorded. Cumulative dosage of antipsychotic medication in a haloperidol equivalent was calculated using conversion rates as described by van Haren et al. (2008) . Healthy comparison subjects had never been mentally ill and had no first-degree family member with a psychotic illness. Parental socioeconomic status, expressed as the highest level of education completed by one of the parents in years, was recorded for all subjects.
The statistical significance of group-differences in demographic characteristics was examined using analysis of variance (ANOVA) for continuous and Chi-square tests for categorical variables. Demographic and clinical characteristics are provided in Table 1 .
Procedures and measures
CASH-based symptom dimensions
All subjects were assessed with the Comprehensive Assessment of Symptoms and History (Andreasen et al., 1992) . Factor analysis of the lifetime-rated symptoms and observational items produced five continuous symptom dimensions. Given the content of the items (see Table 1 in Derks et al., in press) , the symptom dimensions were described as "negative", "positive", "disorganization", "mania" and "depression". The procedure to calculate factor scores for each of the five dimensions was described in detail in Derks et al. (in press ) Briefly, a total of 67 lifetime-rated items were included in confirmatory factor analyses in a sample of 4286 schizophrenia and bipolar patients, relatives of schizophrenia patients and community controls, recruited in the GROUP study, Utrecht Schizophrenia Project, and the First-Episode Schizophrenia Research Program. For the present study, estimation of factor scores was based on the entire sample of 4286 subjects, from which individual dimension scores were extracted. It should be noted that subjects with more than 20% but less than 25% missing items were included in the analyses for this paper while they were excluded from Derks et al. (in press ).
Cognitive functioning
Global cognitive functioning, as measured by total IQ, was assessed with four subtests of the Dutch version of the Wechsler Adult Intelligence Scale (WAIS) (Stinissen et al., 1970) : Vocabulary, Comprehension, Block Design and Picture Arrangement. Mean raw scores were transformed into the corresponding C-score of the WAIS for each subtest. Since the WAIS has a total of 11 subtests, a proximate total sum of C-scores was derived by adding the C-scores of the four subtests, divided by 4 and multiplied by 11, as follows: proximate sum of C-scores =(C-score of four subtests/ 4)× 11. An estimated full-scale IQ was derived by transforming the sum of C-scores into IQ-equivalents using transformation tables provided by the WAIS. IQ-scores were corrected for an estimated IQ gain of 0.25 point per year for the number of years between 1971 and the date of the WAIS investigation (Flynn, 2009) . IQ was assessed in 82 patients and 95 controls. Mean IQ and range are provided in Table 1 .
Functional outcome
The Camberwell Assessment of Need (CAN; Phelan et al., 1995 ) was obtained at various intervals during follow-up. The CAN is an instrument to identify the individual needs of people with severe mental illness. It consists of 24 items covering a wide range of human needs, such as shelter and the company of other people, as well as needs specific to people suffering from mental illness. CAN-data was available for 95 out of 105 patients. A selection of items from the CAN-interview at 5-year follow-up was used. Nine items that reflect basic daily life skills were selected: accommodation, food, household skills, self-care, daily activities, company of others, intimate relationships, telephone and transport. The number of met and unmet needs for these items was determined per patient and was used as a measure of global functioning at 5-year follow-up (see Table 1 ).
MRI acquisition and measurements
Magnetic Resonance Imaging (MRI) scans were acquired on a 1.5 T Philips NT scanner at inclusion and 5-year follow-up with a mean (SD) MRI interval of 4.98 (0.45) years. All images were corrected for inhomogeneities in the magnetic field according to the method described by Sled et al. (1998) . In-house developed software was used to measure total brain, gray and white matter, cerebellar en ventricle volumes. For a description of MRI procedure and segmentation see Schnack et al. (2001a,b) , Hulshoff Pol et al. (2001) and Brouwer et al. (2010) .
Statistical analysis
Mean global brain volumes at baseline and 5-year follow-up and standard deviations were calculated. Volume change over time per subject was calculated for all brain volumes by subtracting the volume at baseline from the volume at follow-up. The percentage volume change during scan interval was calculated by dividing the volume change by the volume at baseline multiplied by 100%. Percentage of volume change per year scan-interval was calculated by dividing the percentage of volume change by the time between MRI scans in years. Mean global brain volumes at baseline and 5-year follow-up and the percentage of volume change per year scan-interval are summarized in Table 2 .
Brain volume data and symptom dimension scores were examined for outliers and normality of distribution. In patients, symptom dimension scores were normally distributed. However, in controls, distributions of dimension scores were not continuous, with the majority of the subjects obtaining a very low score while a minority showed elevated dimension scores.
To assess whether symptom dimension scores are associated with brain volume change over time in schizophrenia patients, we performed linear regression analyses in the patient sample in which the percentage of volume change per year scan-interval for each of the global brain volumes was the dependent variable. To correct for age, gender and intracranial volume, these variables were included as predictors. Dimension scores were included in the model if this resulted in a significant improvement in the prediction of brain volume change, according to forward stepwise analysis. As antipsychotic medication may influence progressive brain volume change, the analyses were repeated with total cumulative medication during scan interval, in haloperidol equivalent, as a covariate in a subgroup of 101 patients for whom medication data was available. In addition, socioeconomic status (i.e., parental level of education), global functional outcome (i.e., CAN) and cognitive functioning (i.e., estimated IQ) were investigated as potential confounders for any significant associations between symptom dimensions and progressive change in global brain volumes.
Based on the observed effects in patients, the relationship between disorganization and progressive brain volume changes was investigated in the healthy comparison subjects. The healthy comparison sample was categorized in two groups based on disorganization dimension scores, because the distribution of dimension scores was not continuous, as mentioned previously. Independent sample t-tests were conducted to investigate the relationship between disorganization dimension scores and brain volume change over time, corrected for age, gender and intracranial volume, in the healthy comparison sample.
We performed multiple tests as we investigated the association between change in six different brain volumes and five symptom dimensions. We did not apply a strict Bonferroni correction as this would control type-I error rate but would result in an increased type-II error rate. A p-value of 0.008 was decided on so that type-I error rate is controlled for the comparison of six brain volumes but should be regarded as explorative for the five symptom dimensions. For the analyses with a single dependent variable (i.e. total cumulative medication, IQ and functional outcome), the p-value was set at 0.05.
Results
Progressive changes in global brain volumes were heterogeneous across individual subjects. On average, total brain and cerebral gray matter volume decreased over time and ventricle volumes increased with patients exhibiting greater change than healthy comparison subjects. Average cerebral white matter and cerebellar volume did not change significantly (see Table 2 ). In patients, progressive decline of global brain volumes was significantly associated with the level of disorganization. Higher levels of disorganization were associated with more pronounced decrease in total brain (β = −0.295, p= 0.003) and cerebellar volume (β = −0.349, pb 0.001) (see Fig. 1 ). To ascertain that the effect in total brain volume decline was not solely driven by the decrease in cerebellar volume, a post-hoc regression analysis with total brain minus cerebellar volume (i.e. total cerebral and brainstem volume) and disorganization score was performed, which also demonstrated a significant association (β= −0.269, p = 0.008). The positive, negative, mania, and depression dimensions were not significantly associated with progressive change in any of the brain volumes (all p > 0.05). Mean (SD) symptom dimensions scores across the two subject groups are provided in Table 3 .
Total cumulative antipsychotic medication in haloperidol equivalent between baseline and 5-year follow-up was not associated with progressive brain volume change or symptom dimension scores. Cognitive functioning (i.e., IQ) was not associated with progressive change in brain volumes. Lower total IQ was, however, significantly associated with higher levels of disorganization (β=−0.258, p =0.021). Functional outcome at 5-year follow-up was significantly associated with change in total brain (β=−0.350, p =0.001), cerebral gray matter (β=−0.260, p=0.013) and lateral ventricle (β=0.281, p=0.007) volume. Functional outcome was not significantly associated with symptom dimension scores. When total cumulative medication, socioeconomic status, functional outcome and cognitive functioning were included as covariates in the regression analyses, the association between disorganization and change in total brain and cerebellar volume remained significant. As disorganization was significantly associated with change in global brain volumes in schizophrenia patients, this association was also investigated in healthy controls. In the healthy comparison sample, disorganization scores were not normally distributed. We therefore created two groups based on a cut-off of the standardized score of −0.250 for the disorganization dimension. The majority of controls (N= 81) scored below −0.250 on disorganization (mean disorganization score= −0.36; SD = 0.05), 19 control subjects scored above −0.250 (mean disorganization score = 0.25; SD = 0.41). Healthy comparison subjects with relatively high disorganization scores had significantly lower total IQ (t(93)= 3.962, p b 0.001, medium sized effect: r = 0.38) than those with low disorganization scores (see Fig. 2 ). Progressive brain volume changes were not significantly associated with the level of disorganization in the healthy comparison subjects.
Discussion
This study investigated the relationship between clinical heterogeneity and variation in progressive structural brain changes in schizophrenia. To this end, the association between individual variation in lifetime rated symptomatology, as measured by five continuous symptom dimensions, and brain volume change over time was examined in 105 schizophrenia patients and 100 healthy comparison subjects. Our main finding is that greater severity of disorganization symptoms is associated with more pronounced decrease of total brain and cerebellar volume over time in schizophrenia patients. Negative, positive, mania and depression symptom dimensions were not associated with brain volume change over time.
Studies examining the relationship between schizophrenia symptom dimensions and disease markers have found that early onset of disease, long duration of illness (Salokangas et al., 2002) and antipsychotic treatment resistance (Rodriguez et al., 1998) are particularly associated with disorganization. This study adds that disorganization is also associated with a pronounced decrease in global brain volume over time. Furthermore, we found that disorganization is associated with decreased intellectual functioning, consistent with a recent metaanalysis showing that more severe disorganization symptoms predict lower IQ (Dibben et al., 2009) . Finally, studies examining the familiality of symptom dimensions, have consistently shown that the disorganization dimension is highly heritable (Rietkerk et al., 2008; McGrath et al., 2009 ). Together, these findings suggest that not only may disorganization be a biologically distinct feature of schizophrenia, the subgroup of patients identified by high scores on the disorganization dimension may also be biologically separate.
Indeed, patients with high levels of disorganization, low IQ and relatively large progressive brain changes resemble the patients described Mean (SD) scores on each of the five symptoms dimensions across the subject groups; and the statistical significance of group-differences. by Kraepelin as suffering from dementia praecox (Kraepelin, 1919) , in particular hebephrenia (Hecker, 1871; Kraepelin, 1919; Kraam, 2009 ).
In fact, in a recent editorial arguing for the replacement of the schizophrenia concept by hebephrenia, Taylor et al. (2010) show that empirical data on psychopathology, clinical course, treatment response and biological and genetic markers do not support the concept of schizophrenia as a medical model. The authors argue that hebephrenia is a more homogenous construct with distinctive and reliably identified clinical features and conclude that hebephrenia is not merely a subtype of schizophrenia: "It is schizophrenia" (Taylor et al., 2010) . A number of longitudinal studies have been performed in which the association between brain volume change and outcome measures is investigated. Milev et al. (2003) showed that small temporal lobe gray matter volume at onset is associated with persistence of hallucinations five years later. Reductions in gray matter volume over time were found to be associated with poor outcome, such as number of hospitalizations (van Haren et al., 2007) , and duration of psychosis (Cahn et al., 2009) . Ho et al. (2003) showed that patients with poor outcome had greater increase in lateral ventricle volumes compared to patients who recovered well. They also showed that greater negative symptom severity at 3-year follow-up was predicted by a greater decline in frontal lobe WM volume and greater enlargement in frontal lobe CSF volume. We have not found an association between change in brain volume and positive and negative symptoms in patients with schizophrenia. This is slightly counterintuitive; on the other hand, the results of previous studies are also rather inconsistent. Our findings show that future studies should include disorganization as a symptom dimension of interest as we find the strongest association between change in total brain volume and the level of disorganization.
Progressive brain volume changes in schizophrenia are sometimes attributed to the effects of antipsychotic medication (e.g., Lewis, 2011) . Interestingly, patients with a greater severity of disorganization symptoms -who, as our results indicate, showed the largest loss of brain volume over time -did not receive higher doses of antipsychotic medication than the other patients. Therefore, antipsychotic medication cannot explain the loss of brain tissue in this subgroup of patients. The association between progressive change in global brain volumes and variation in symptomatology (i.e. level of disorganization), in the absence of differential exposure to medication, suggests that the progressive brain changes are an integral part of the pathophysiology of the illness. In fact, studies in individuals at high genetic risk of schizophrenia show that progressive brain changes predate not just antipsychotic treatment, but even illness onset (McIntosh et al., 2011) .
The neuropathologic mechanism underlying disorganization may thus be different from the neuropathology leading to other symptom dimensions. In a review of dopamine dysfunction in schizophrenia, Howes and Kapur (2009) report that dopamine hyperfunction is closely linked to the psychosis dimension, but predict that nonpsychotic dimensions of schizophrenia would not show similar dopamine abnormalities, thus dissociating psychosis from the other dimensions of schizophrenia. The glutamate hypothesis may be better able to explain schizophrenia features other than psychosis. Indeed, the concept of glutamate dysfunction in schizophrenia originates from observations that drugs acting on the glutamate N-methyl-D-aspartate (NMDA) receptor (e.g. phenylcyclidine, ketamine) also induce the cognitive and negative features of schizophrenia, while dopamine agonists only produce positive (psychotic) symptoms (Krystal et al., 1994) . Dysfunction of the glutamatergic system, through NMDA-hypofunction, may also account for the progressive brain changes in schizophrenia: high extracellular concentrations of glutamate cause excessive calcium influx through NMDA-channels, resulting in cell damage and cell death. Moreover, glutamate-induced neurotoxicity can be reversed by NMDA receptor antagonists in neuronal cultures. Sustained NMDAhypofunction may thus lead to not only neurochemical but also neuroplastic changes in the brain (Gunduz-Bruce, 2009).
Interestingly, there is some evidence from genetic studies that the glutamatergic system is involved in the disorganization dimension. In a genome wide linkage study, an association was found between a factor-analytically derived schizophrenia subtype with severe disorganization and negative symptoms and a susceptibility locus on chromosome 1q23-25 (Holliday et al., 2009 ). The best-studied gene in that region is the regulator of G protein signaling 4 (RGS4) gene, which is involved in glutamate systems and is thought to have downstream effects on the NMDA receptor (Volk et al., 2010) . RGS4 expression is downregulated in the prefrontal cortex and superior temporal gyrus in schizophrenia (Prasad et al., 2005) . Furthermore, genetic variation in RGS4 has been associated with brain volume alterations in schizophrenia patients and healthy subjects (Bowden et al., 2007) . Thus, dysregulation of the glutamate system may, possibly through genetic variation in RGS4, explain the association between disorganization and progressive brain volume decline in schizophrenia.
The association between disorganization and progressive decrease of cerebellar volume is particularly interesting in light of the concept of "cognitive dysmetria" (Andreasen et al., 1998) . In this model, all schizophrenia symptoms are secondary to a core cognitive deficit, resulting from a disruption in brain circuitry involving the cerebellum. Alterations in cerebellar volume have been associated with disorganization symptoms previously. In a cross-sectional study, Nenadic et al. (2010) found cerebellar volume deficits in a disorganized subgroup of 99 chronic stable schizophrenia patients. However, evidence for cerebellar abnormalities in schizophrenia is inconclusive (Picard et al., 2008 ) and the present study did not establish decline of cerebellar volume in schizophrenia patients versus healthy comparison subjects. One possible explanation for these inconsistencies is that only a subgroup of schizophrenia patients (i.e. disorganized patients) exhibits cerebellar volume change.
Some limitations should be taken into account when interpreting our findings. First, this study examined only global, and not regional, changes in brain volumes. Second, there was large heterogeneity with respect to duration of illness and age. Third, only a small number of healthy comparison subjects (n = 19) had relatively high disorganization scores, mandating caution when interpreting the association between disorganization dimension score and cognitive functioning in healthy individuals. Finally, in the majority of the subjects the CASH interview was completed at 5-year follow-up. Therefore, the direction of causality cannot be determined and it remains unresolved how the association between disorganization and progressive brain volume changes arises.
In conclusion, we found that heterogeneity in progressive brain volume changes in schizophrenia is particularly associated with the level of disorganization. Patients with high levels of disorganization exhibited a larger decrease in global brain volumes over time and are also characterized by lower total IQ. We propose that these patients form a biologically and genetically distinct subgroup of schizophrenia patients. The identification of this subgroup of patients will facilitate detection of causal genetic factors in schizophrenia.
